ANIK Relative Valuation
ANIK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ANIK is overvalued; if below, it's undervalued.
Historical Valuation
Anika Therapeutics Inc (ANIK) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 202.80. The fair price of Anika Therapeutics Inc (ANIK) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：9.49
Fair
52.72
PE
1Y
3Y
5Y
Trailing
Forward
15.98
EV/EBITDA
Anika Therapeutics Inc. (ANIK) has a current EV/EBITDA of 15.98. The 5-year average EV/EBITDA is -49.69. The thresholds are as follows: Strongly Undervalued below -844.12, Undervalued between -844.12 and -446.90, Fairly Valued between 347.53 and -446.90, Overvalued between 347.53 and 744.75, and Strongly Overvalued above 744.75. The current Forward EV/EBITDA of 15.98 falls within the Historic Trend Line -Fairly Valued range.
-8.38
EV/EBIT
Anika Therapeutics Inc. (ANIK) has a current EV/EBIT of -8.38. The 5-year average EV/EBIT is -255.52. The thresholds are as follows: Strongly Undervalued below -1923.44, Undervalued between -1923.44 and -1089.48, Fairly Valued between 578.44 and -1089.48, Overvalued between 578.44 and 1412.40, and Strongly Overvalued above 1412.40. The current Forward EV/EBIT of -8.38 falls within the Historic Trend Line -Fairly Valued range.
1.18
PS
Anika Therapeutics Inc. (ANIK) has a current PS of 1.18. The 5-year average PS is 2.47. The thresholds are as follows: Strongly Undervalued below 0.77, Undervalued between 0.77 and 1.62, Fairly Valued between 3.32 and 1.62, Overvalued between 3.32 and 4.17, and Strongly Overvalued above 4.17. The current Forward PS of 1.18 falls within the Undervalued range.
0.00
P/OCF
Anika Therapeutics Inc. (ANIK) has a current P/OCF of 0.00. The 5-year average P/OCF is 150.66. The thresholds are as follows: Strongly Undervalued below -805.98, Undervalued between -805.98 and -327.66, Fairly Valued between 628.97 and -327.66, Overvalued between 628.97 and 1107.29, and Strongly Overvalued above 1107.29. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
66.01
P/FCF
Anika Therapeutics Inc. (ANIK) has a current P/FCF of 66.01. The 5-year average P/FCF is 6.00. The thresholds are as follows: Strongly Undervalued below -595.31, Undervalued between -595.31 and -294.66, Fairly Valued between 306.65 and -294.66, Overvalued between 306.65 and 607.31, and Strongly Overvalued above 607.31. The current Forward P/FCF of 66.01 falls within the Historic Trend Line -Fairly Valued range.
Anika Therapeutics Inc (ANIK) has a current Price-to-Book (P/B) ratio of 0.93. Compared to its 3-year average P/B ratio of 1.39 , the current P/B ratio is approximately -33.14% higher. Relative to its 5-year average P/B ratio of 1.52, the current P/B ratio is about -38.83% higher. Anika Therapeutics Inc (ANIK) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -1.35%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -0.37% , the current FCF yield is about -100.00% lower.
0.93
P/B
Median3y
1.39
Median5y
1.52
0.47
FCF Yield
Median3y
-1.35
Median5y
-0.37
Competitors Valuation Multiple
The average P/S ratio for ANIK's competitors is 0.00, providing a benchmark for relative valuation. Anika Therapeutics Inc Corp (ANIK) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -28.22%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ANIK decreased by 42.35% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -5.60 to -9.59.
The secondary factor is the Revenue Growth, contributed -28.22%to the performance.
Overall, the performance of ANIK in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Anika Therapeutics Inc (ANIK) currently overvalued or undervalued?
What is Anika Therapeutics Inc (ANIK) fair value?
How does ANIK's valuation metrics compare to the industry average?
What is the current P/B ratio for Anika Therapeutics Inc (ANIK) as of Dec 05 2025?
What is the current FCF Yield for Anika Therapeutics Inc (ANIK) as of Dec 05 2025?
What is the current Forward P/E ratio for Anika Therapeutics Inc (ANIK) as of Dec 05 2025?